Toward a Core Domain Set for Glucocorticoid Impact in Inflammatory Rheumatic Diseases: The OMERACT 2018 Glucocorticoid Impact Working Group

Jonathan T L Cheah; Rachel J Black; Joanna C Robson; Iris Y Navarro-Millán; Sarah R Young; Pamela Richards; Susan Beard; Lee S Simon; Susan M Goodman; Sarah L Mackie; Catherine L Hill

doi:10.3899/jrheum.181082

Toward a Core Domain Set for Glucocorticoid Impact in Inflammatory Rheumatic Diseases: The OMERACT 2018 Glucocorticoid Impact Working Group

J Rheumatol. 2019 Sep;46(9):1179-1182. doi: 10.3899/jrheum.181082. Epub 2019 Jan 15.

Authors

Jonathan T L Cheah^{1

2}, Rachel J Black^{3

4}, Joanna C Robson^{3

4}, Iris Y Navarro-Millán^{3

4}, Sarah R Young^{3

4}, Pamela Richards^{3

4}, Susan Beard^{3

4}, Lee S Simon^{3

4}, Susan M Goodman^{3

4}, Sarah L Mackie^{3

4}, Catherine L Hill^{3

4}

Affiliations

¹ From the Division of Rheumatology, Hospital for Special Surgery; Department of Medicine, and the Division of General Internal Medicine, Weill Cornell Medicine, New York; Department of Social Work, Binghamton University, Binghamton, New York; SDG LLC, Cambridge, Massachusetts, USA; Rheumatology Unit, Royal Adelaide Hospital; Discipline of Medicine, The University of Adelaide; Rheumatology Unit, The Queen Elizabeth Hospital, Adelaide, Australia; Faculty of Health and Applied Science, University of the West of England; School of Clinical Science, University of Bristol, Bristol; Leeds Biomedical Research Centre, Leeds Institute of Rheumatic and Musculoskeletal Medicine; Chapel Allerton Hospital, University of Leeds, Leeds, UK. cheahj@hss.edu.
² J.T. Cheah, MBBS, Fellow, Division of Rheumatology, Hospital for Special Surgery, and Department of Medicine, Weill Cornell Medicine; R.J. Black, MBBS, Consultant Rheumatologist, Rheumatology Unit, Royal Adelaide Hospital, and Discipline of Medicine, The University of Adelaide; J.C. Robson, MBBS, PhD, MRCP, Consultant Senior Lecturer in Rheumatology, Faculty of Health and Applied Science, University of the West of England, and School of Clinical Science, University of Bristol; I.Y. Navarro-Millán, MD, MSPH, Assistant Professor of Medicine, Division of General Internal Medicine, Weill Cornell Medicine, and Division of Rheumatology, Hospital for Special Surgery; S.R. Young, PhD, LMSW, Assistant Professor, Department of Social Work, Binghamton University; P. Richards, HNC (Business Studies), OMERACT Patient Research Partner; S. Beard, BMus, OMERACT Patient Research Partner; L.S. Simon, MD, Principal, SDG LLC; S.M. Goodman, MD, Professor of Clinical Medicine, Division of Rheumatology, Hospital for Special Surgery, and Department of Medicine, Weill Cornell Medicine; S.L. Mackie, MB BCh, PhD, MRCP, Leeds Biomedical Research Centre, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, and University of Leeds; C.L. Hill, MBBS, MSc, MD, FRACP, Clinical Professor, Rheumatology Unit, The Queen Elizabeth Hospital, and Rheumatology Unit, Royal Adelaide Hospital, and Discipline of Medicine, The University of Adelaide. cheahj@hss.edu.
³ From the Division of Rheumatology, Hospital for Special Surgery; Department of Medicine, and the Division of General Internal Medicine, Weill Cornell Medicine, New York; Department of Social Work, Binghamton University, Binghamton, New York; SDG LLC, Cambridge, Massachusetts, USA; Rheumatology Unit, Royal Adelaide Hospital; Discipline of Medicine, The University of Adelaide; Rheumatology Unit, The Queen Elizabeth Hospital, Adelaide, Australia; Faculty of Health and Applied Science, University of the West of England; School of Clinical Science, University of Bristol, Bristol; Leeds Biomedical Research Centre, Leeds Institute of Rheumatic and Musculoskeletal Medicine; Chapel Allerton Hospital, University of Leeds, Leeds, UK.
⁴ J.T. Cheah, MBBS, Fellow, Division of Rheumatology, Hospital for Special Surgery, and Department of Medicine, Weill Cornell Medicine; R.J. Black, MBBS, Consultant Rheumatologist, Rheumatology Unit, Royal Adelaide Hospital, and Discipline of Medicine, The University of Adelaide; J.C. Robson, MBBS, PhD, MRCP, Consultant Senior Lecturer in Rheumatology, Faculty of Health and Applied Science, University of the West of England, and School of Clinical Science, University of Bristol; I.Y. Navarro-Millán, MD, MSPH, Assistant Professor of Medicine, Division of General Internal Medicine, Weill Cornell Medicine, and Division of Rheumatology, Hospital for Special Surgery; S.R. Young, PhD, LMSW, Assistant Professor, Department of Social Work, Binghamton University; P. Richards, HNC (Business Studies), OMERACT Patient Research Partner; S. Beard, BMus, OMERACT Patient Research Partner; L.S. Simon, MD, Principal, SDG LLC; S.M. Goodman, MD, Professor of Clinical Medicine, Division of Rheumatology, Hospital for Special Surgery, and Department of Medicine, Weill Cornell Medicine; S.L. Mackie, MB BCh, PhD, MRCP, Leeds Biomedical Research Centre, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, and University of Leeds; C.L. Hill, MBBS, MSc, MD, FRACP, Clinical Professor, Rheumatology Unit, The Queen Elizabeth Hospital, and Rheumatology Unit, Royal Adelaide Hospital, and Discipline of Medicine, The University of Adelaide.

Abstract

Objective: To understand the effects of glucocorticoids (GC), which are of importance to patients.

Methods: The results of 2 literature reviews, a patient survey, and a qualitative study were presented.

Results: No validated instrument exists to evaluate GC effect on patients. Survey data revealed skin thinning/bruising, sleep disturbance, and weight gain as the most frequent adverse effects. The qualitative research yielded rich data covering rapid benefits and physical and emotional consequences of GC.

Conclusion: It was agreed that a patient-reported outcome to measure GC effect was required and a research agenda was developed for this goal.

Keywords: ADVERSE EFFECTS; GLUCOCORTICOIDS; OMERACT; OUTCOME ASSESSMENT; RHEUMATIC DISEASES.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Glucocorticoids / adverse effects
Glucocorticoids / therapeutic use*
Humans
Patient Reported Outcome Measures
Rheumatic Diseases / drug therapy*
Treatment Outcome

Substances

Glucocorticoids

Abstract

Publication types

MeSH terms

Substances

Grants and funding